Evidence map›Paper›PMID 39865563›Full record

Trial reportESC heart failure2025

Association of baseline eGFR and incident heart failure on patients receiving intensive blood pressure treatment.

Li Haonan, He Qiaorui, Zhu Wenqing, Zhang Yanjun, Pingcuo Wangjia, Yu Shikai, Deji Zhuoga, Zhang Yi, Zhao Yifan

Abstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in ESC heart failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Trial
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Li HaonanHeart Center, Shanghai Tenth People's Hospital, School of medicine, Tongji University, Shanghai, China.
He QiaoruiHeart Center, Shanghai Tenth People's Hospital, School of medicine, Tongji University, Shanghai, China.
Zhu WenqingTongji University School of Medicine, Tongji University, Shanghai, China.
Zhang YanjunDepartment of Cardiology, Shigatse People's Hospital, Tibet, China.
Pingcuo WangjiaDepartment of Cardiology, Shigatse People's Hospital, Tibet, China.
Yu ShikaiHeart Center, Shanghai Tenth People's Hospital, School of medicine, Tongji University, Shanghai, China.
Deji ZhuogaDepartment of Cardiology, Shigatse People's Hospital, Tibet, China.
Zhang YiHeart Center, Shanghai Tenth People's Hospital, School of medicine, Tongji University, Shanghai, China.
Zhao YifanHeart Center, Shanghai Tenth People's Hospital, School of medicine, Tongji University, Shanghai, China.ORCID https://orcid.org/0009-0001-5028-9151

Funding

Cardiac rehabilitation fund by the International Medical Exchange Foundation Z-2019-42-1908-3Grant for the Construction of Innovative Flagship Hospital for Integrated Traditional Chinese and Western Medicine ZY(2021-2023)-0205-05Health Youth Talent Project of Shanghai Municipal Health Commission 2022YQ023National Nature Science Foundation of China 82170388National Nature Science Foundation of China 82370300Shanghai Municipal Health Commission Clinical Research Project 20214Y0152Shanghai Technology Research Leader Program 21XD1434700
6 · The paper itself

Abstract

aimsWe aim to elucidate the association of baseline eGFR and incident heart failure on patients receiving intensive BP treatment. METHODS AND

resultsA post hoc analysis was conducted on the SPRINT database. Multivariab le Cox regression and interaction restricted cubic spline (RCS) analysis were performed to investigate the interaction between baseline eGFR and intensive BP control on heart failure prevention. The primary endpoint focused on incident heart failure. The study cohort comprised 8369 adults with a mean [SD] age of 68 [59-77] years, including 2940 women (35.1%). Over a median [IQR] follow-up period of 3.9 [2.0-5.0] years, 183 heart failure events were recorded. A significant interaction was observed between baseline eGFR and treatment groups in terms of heart failure prevention (Interaction P = 0.012). The risk of heart failure showed a sharp slope until eGFR = 75 mL/min/1.73 m

conclusionsAmong nondiabetic hypertensive patients, baseline eGFR serves as a crucial indicator for assessing the risk reduction potential of intensive BP control in heart failure prevention, with 75 mL/min/1.73 m

Indexed as

Antihypertensive AgentsBlood PressureGlomerular Filtration RateHeart FailureHypertensionAgedFemaleFollow-Up StudiesHumansIncidenceMaleMiddle AgedRetrospective StudiesRisk FactorsAntihypertensive AgentsCut‐off valueEstimated glomerular filtration rateIncident heart failureIntensive blood pressure control

Identifiers

PMID39865563
PMCPMC12055372

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.